Amendments to Claims

In the Claims:

Prior to further examination of this application, please amend the claims as shown below.

1. (*Canceled*)

2. (*Currently amended*) The RNAi molecule of claim ~~41~~ that is a single stranded siRNA that forms a hairpin structure.

3. (*Currently amended*) The RNAi molecule of claim ~~41~~ that is a double stranded siRNA.

4. (*Currently amended*) An interfering RNA (RNAi) molecule that comprises ~~The RNAi molecule of claim 1 that (i) comprises, or (ii) hybridizes to a Met target sequence that comprises, a sequence selected from the group consisting of: (a) SEQ ID NO:9; (b) SEQ ID NO:10; (c) SEQ ID NO:11; (d) SEQ ID NO:12; (e) SEQ ID NO:13; (f) SEQ ID NO:14; (g)~~ SEQ ID NO:15~~; (h) SEQ ID NO:16; (i) SEQ ID NO:17; and (j) SEQ ID NO:18~~.

5-7. (*Canceled*)

8. (*Currently amended*) A DNA molecule encoding the RNAi molecule of claim ~~41~~.

9. (*Currently Amended*) An expression construct comprising DNA that encodes the RNAi molecule of claim ~~41~~ operatively linked to a promoter that drives the expression of said RNAi

molecule in a c-*met*-expressing cell.

10. (*Original*) An expression construct comprising the DNA molecule of claim 8.

11. (*Currently Amended*) The expression construct of claim 9, wherein a promoter is one that drives the expression of said RNAi molecule in a c-*met*-expressing tumor or cancer cell.

12. (*Previously presented*) The expression construct of claim 11 wherein the promoter is a polIII promoter.

13. (*Original*) The expression construct of claim 12 wherein the polIII promoter is a U6 promoter.

14. (*Previously presented*) A viral vector comprising the expression construct of claim 9.

15. (*Original*) The viral vector of claim 14 that is a transient expression vector.

16. (*Currently amended*) The viral vector of claim 14 ~~13~~ that is a stable expression vector.

17. (*Previously presented*) The viral vector of claim 14 that is an adenoviral vector.

18. (*Original*) The adenoviral vector of claim 17 that is an Ad5 viral vector.

19. (*Original*) The Ad5 viral vector of claim 18 selected from the group consisting of: (a) si-mMet-Ad5^{57}; (b) si-mMet-Ad5^{60}; (c) si-mMet-Ad5^{110}; (d) si-mMet-Ad5^{178}; (e) si-hMet-Ad5^{16}; (f) si-hMet-Ad5^{62}; (g) si-hMet-Ad5^{221}; (h) si-dMet-Ad5^{111}; (i) si-dMet-Ad5^{197}; and (j) si-dMet-Ad5^{223}.

20. (*Original)* The Ad5 viral vector of claim 19 wherein the vector is si-hMet-Ad5^{16}, si-hMet-Ad5^{62}; or si-hMet-Ad5^{221}.

21-37. (*Canceled*)

38. (*Previously presented*) A method of treating a c-*met*$^{+}$ tumor or cancer in a subject, comprising administering to the subject by an effective route, an amount of the viral vector of claim 14 effective for inhibiting expression of c-*met* and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said tumor or cancer cells.

39-47. (*Canceled*)

48. (*Previously presented*) The method of claim 38 wherein the tumor or cancer is glioblastoma, prostate or gastric.

49. (*Previously presented*) A method of treating a c-*met*$^{+}$ tumor or cancer in a subject,

comprising administering to the subject by an effective route, an amount of the viral vector of claim 19 effective for inhibiting expression of c-*met* and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said tumor or cancer cells.

50. (*Previously presented*) The method of claim 49 wherein the tumor or cancer is glioblastoma, prostate or gastric.